Ipsen
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Ipsen sits in the top decile of US sponsors by registered trial count (#268 of 15,742 sponsors by registered trial count).
Ipsen: 85 sponsored US clinical trials, 16 recruiting.
Ipsen sponsors 85 registered US clinical trials on ClinicalTrials.gov, 16 of them currently recruiting, and 50 completed. 33 of these trials are in Phase 3-4 (later-stage) and 28 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Primary Biliary Cholangitis, with 3 trials.
Top-decile sponsor footprint
Ipsen ranks in the top decile of sponsors by registered trial count (#268 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
50 of 62 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
85 total, page 2 of 2
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
NCT02551991
Validation Study of the SAGIT® Instrument in Acromegaly
NCT02539927
Attainment of Person-centred Goals After Botulinum Toxin Treatment for Upper Limb Spasticity in Real Life Practice
NCT02454803
Efficacy And Safety Of Dysport In The Treatment Of Upper Limb Spasticity In Children
NCT02106351
Long Term Safety And Effectiveness Of Dysport® In Adults With Cervical Dystonia
NCT01753336
SAGIT for Classification of Patients With Acromegaly in Clinical Practice
NCT02231593
Efficacy and Safety of DYSPORT® Using 2mL Dilution in Adults With Cervical Dystonia.
NCT01753310
Phase IV-Cervical Dystonia-INTEREST IN CD2
NCT01753349
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
NCT01770353
Dysport® Adult Upper Limb Spasticity Extension Study
NCT01313312
Dysport® Pediatric Lower Limb Spasticity Follow-on Study
NCT01251380
Dysport® Adult Upper Limb Spasticity
NCT01313299
Dysport® Pediatric Lower Limb Spasticity Study
NCT01249417
Dysport® Adult Lower Limb Spasticity Follow-on Study
NCT01251367
DYSPORT™ Clinical & Health Economics Outcomes Registry in Cervical Dystonia
NCT01314365
Dysport® Adult Lower Limb Spasticity Study
NCT01249404
Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy
NCT01251354
Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly
NCT00994214
An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
NCT00774930
Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour
NCT00842348
BN83495 in Prostate Cancer
NCT00790374
Somatuline® Depot (Lanreotide) for Acromegaly Post-Marketing Observational Study
NCT00686348
rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency
NCT00572156
Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment
NCT00489255
Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
NCT00447499
Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours
NCT00353496
IGFD Registry: A Patient Registry for Monitoring Long-term Safety and Efficacy of Increlex
NCT00747604
Open-label Extension Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
NCT00288509
Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
NCT00257660
Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency
NCT00125190
Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome
NCT00092287
Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency
NCT00125164
Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm
NCT00234507
Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly
NCT00234572
Long-Term Treatment With rhIGF-1 in GHIS
NCT00571727
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 13 |
| Phase 2 | 15 |
| Phase 3 | 30 |
| Phase 4 | 3 |
Therapeutic Areas
What is open in the Ipsen pipeline
16 recruiting of 85 indexed (19% open); 50 completed (59%).
Phase mix: 33 late (III/IV) vs 28 early (I/II) (balanced across stages).
Top condition: Primary Biliary Cholangitis (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Ipsen: open-pipeline peers nationwide
Peers matched on 85 registered trials and 19% open enrollment, not the therapeutic-area sidebar.
Ipsen sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 85 trials (± recruiting share)
- Intermountain Health Care · 85 trials · 13% recruiting
- Seagen · 84 trials · 0% recruiting
- Ferring Pharmaceuticals · 83 trials · 5% recruiting
- National Jewish Health · 83 trials · 8% recruiting
Sponsors near 19% open enrollment (± trial volume)
- Spaulding Rehabilitation Hospital · 19% recruiting · 101 trials
- Medical University of South Carolina · 19% recruiting · 755 trials
- EyePoint Pharmaceuticals · 19% recruiting · 16 trials
- Hebrew SeniorLife · 19% recruiting · 32 trials
Related
What to do with this Ipsen page
85 registered trials is a research-attention snapshot, not an endorsement of Ipsen or any single study.
- 16 of Ipsen's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Primary Biliary Cholangitis is the condition Ipsen studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Primary Biliary Cholangitis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Ipsen pipeline card: 85 registered trials from official public datasets.Report a data error.